GlobeNewswire Inc | Aug 17, 2021 08:00AM EDT

August 17, 2021

PETACH TIKVA, Israel, Aug. 17, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes, announced today that its Co-Founder and Chief Scientific Officer Dr. Noam Emanuel, will deliver a virtual presentation at the first World Association against Infection in Orthopaedics and Trauma (WAIOT) Congress on August 28, 2021.

The virtual presentation will be a part of the Septic Non-Union and Bone Loss Management session. The presentation details can be found below:

Location Room 3Lecture Number 0 41Time 16:11 16:16 CEST Presentation Title: Improved Healing of Gustilo Type IIIA and IIIB Open Long Bone Fractures Treated with Local Biodegradable Prolonged Release Antibiotic Formulated Bone Graft During the First Surgical Intervention Post-Surgery: A Prospective, Randomized Clinical TrialPresenter Dr. Noam Emanuel, PolyPid

WAIOT is the first and the largest worldwide scientific association, focused on bone, joints, biofilms- and implant-related infections. The event will be attended by 1,700 members coming together virtually from 101 countries.

AboutPolyPid

PolyPid Ltd.(Nasdaq:PYPD) is a late-stage biopharmaceutical company focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes. PolyPids proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over durations ranging from several days to months. PolyPids lead product candidate D-PLEX100is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).

For additional company information, please visit http://www.polypid.comand follow us onTwitterandLinkedIn.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its ongoing clinical trials, plans to use the guidance provided by the FDA to progress with its SHIELD I program, the timing of top-line results of the SHIELD I trial, and the size and design of the SHIELD I trial. Forward-looking statements are not historical facts, and are based upon managements current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that managements expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Companys reports filed from time to time with the Securities and Exchange Commission (SEC), including, but not limited to, the risks detailed in the Companys Annual Report on Form 20-F filed on March 5, 2021. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Corporate ContactPolyPid, Ltd.Dikla Czaczkes AkselbradEVP & CFO+972-747195700

Investor ContactBob YedidLifeSci Advisors646-597-6989bob@lifesciadvisors.com

Media ContactNechama Feuerstein551-444-0784Nechama.Feuerstein@finnpartners.com